Shin Nippon Biomedical Laboratories, Ltd. (TYO:2395)

TYO:2395 Revenue

In the fiscal year ending March 31, 2026, Shin Nippon Biomedical Laboratories had annual revenue of 32.52B JPY with 0.35% growth. Shin Nippon Biomedical Laboratories had revenue of 11.33B in the quarter ending March 31, 2026, with 11.31% growth.

• Revenue: 32.52B
• Revenue Growth: +0.35%
• P/S Ratio: 1.40
• Revenue / Employee: 21.37M
• Employees: 1,522
• Market Cap: 45.46B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2026	32.52B	111.96M	0.35%
Mar 31, 2025	32.41B	5.96B	22.54%
Mar 31, 2024	26.45B	1.36B	5.42%
Mar 31, 2023	25.09B	7.34B	41.37%
Mar 31, 2022	17.75B	2.64B	17.46%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 1, 2026

Data Sources Report a data error